Keytruda receives FDA approval for the first time to treat early-stage kidney cancer to reduce the risk of recurrence by 32%

Today, Merck & Co.

Renal cell carcinoma is the most common type of kidney cancer.

This approval is based on the results of a pivotal Phase 3 clinical trial

In addition, the data released at this year's ESMO conference show that Keytruda also shows a good trend in reducing the risk of death in patients, reducing the risk of death in patients by 46% compared with placebo

▲The results of Keytruda in the pivotal Phase 3 clinical trial (Image source: Merck official website)

"The adjuvant treatment options for early renal cell carcinoma are limited, and Keytruda's approval provides a new treatment option for patients with a higher risk of recurrence

The use of immunotherapy to treat early-stage cancer patients, reduce disease recurrence, and improve cancer cure rate is the research direction of many pharmaceutical companies

We look forward to the combination of the application of immunotherapy in early cancer and more effective early cancer screening methods, so that more patients can be diagnosed earlier, receive effective treatment earlier, and embark on the road to cure

Reference materials:

[1] FDA Approves Merck's KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery.

[2] Merck Oncology Overview.